

DAFTAR PUSTAKA

1. Yano Y. Hepatitis B virus infection in Indonesia. *World J Gastroenterol.* 2015; 21: 10714.
2. WHO. Global Hepatitis Report 2024. Action for access in low and middle income countries. Geneva. 2024.
3. Kementerian Kesehatan RI. Hasil Utama Riskesdas 2018. Jakarta: *Balitbangkes* 2018: 34.
4. Kisseleva T, Brenner T. Molecular and cellular mechanisms of liver fibrosis and its regression. *Nat Rev Gastroenterol Hepatol.* 2020; 18: 151-66.
5. Jones F, Sembiring J, Zain LH. Akurasi Diagnostik Fibrosis Hati berdasarkan Rasio Red Cell Distribution Width (RDW) dan Jumlah Trombosit Dibanding dengan fibroscan pada Penderita Hepatitis B Kronik. *Glob Med Health Commun GMHC.* 2016; 4: 104.
6. Zuniga-Anguilar E, Ramirez-Fernandez O. Fibrosis and hepatic regeneration mechanism. *Transl Gastroenterohepatol.* 2022; 7 (9): 1-23
7. Xiong M, Li J, Yang S, Zeng F, Ji Y, Liu J, *et al.* Influence of Gender and Reproductive Factors on Liver Fibrosis in Patients with Chronic Hepatitis B Infection: *Clin Transl Gastroenterol.* 2019; 10: 85
8. Stahl EC, Haschak MJ, Popovic B, Brown BN. Macrophages in the Aging Liver and Age-Related Liver Disease. *Front Immunol.* 2018; 9: 2795.
9. Du X, Wang J, Shao L, Hu X, Yang C, Shen L, *et al.* Histological improvement of long-term antiviral therapy in chronic Hepatitis B patients with persistently normal alanine aminotransferase levels. *J Viral Hepat.* 2013; 20: 328–35.
10. WHO. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva. 2024: 53-62.

11. Fadrian. Terapi antiviral pada sirosis hati dekompensata terkait infeksi virus Hepatitis B. *Maj Kedokt Andalas*. 2016; 39: 35.
12. Litwin M, Agnieszka M, Jakub P, Patrycja K, Witek A, Martyna k, Stanisław J. *et al* Treatment of chronic hepatitis B: options, monitoring, special cases and adverse effects. *Journal of Education Health and Sport*. 2025: 77.
13. Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. *J Hepatol*. 2012; 56: 1171–80.
14. Li X, Jin Q, Xu H, Zhang Z, Zhou H, Yan D *et al*. Chronic Hepatitis B patients with high liver fibrosis levels should receive antiviral treatment. *Exp Ther Med*. 2017; 13: 3624–30.
15. Calvaruso V, Craxì A. Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? *Liver Int*. 2014; 34: 85–90.
16. Papachrysos N, Hytiroglou P, Papalavrentios L, Sinakos E, Kouvelis I, Akriviadis E, *et al*. Antiviral therapy leads to histological improvement of HBeAg-negative chronic Hepatitis B patients. *Ann Gastroenterol*. 2015.
17. Wahyuni RD. Analisis derajat fibrosis hati dengan fibroscan, indeks fib4, king's score dan APRI score pada penyakit Hepatitis kronis. 2016; 2.
18. Li Y, Huang YS, Wang ZZ, Yang ZR, Sun F, Zhan SY *et al*. Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic Hepatitis B. *Aliment Pharmacol Ther*. 2016; 43(4):458-69.
19. Jiang K, Zhang L, Li J, Hu H, Huang Q, Qiu T, *et al*. Diagnostic efficacy of FibroScan for liver inflammation in patients with chronic Hepatitis B: a single-center study with 1185 liver biopsies as controls. *BMC Gastroenterol*. 2022 ;22(1):37.
20. Lesmana R, Irsan H, Rino A, Sanityoso A, Djumhana A, Setiawan P. *Konsensus Nasional Penatalaksanaan Hepatitis B*. PPHI: Jakarta, 2017.

21. Lee SW, Kim SM, Hur W, Kang B-Y, Lee HL, Nam H, *et al.* Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K/Akt/mTOR signaling pathway. *PLoS ONE*. 2021; 16(12):1-14.
22. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, *et al.* Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic Hepatitis B: a 5-year open-label follow-up study. *Lancet*. 2013; 381(9865):468–75.
23. Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van BF, Buti M, *et al.* Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic Hepatitis B. *Journal of hepatology*. 2020; 73(5):1037–45
24. Mahmood F, Xu R, Awan MUN, Song Y, Han Q, Xia X. HBV Vaccines: Advances and Development. *Vaccine*. 2023;11.1862: 1-26
25. World Health Organization. Global hepatitis report 2024. World Health Organization; Geneva. 2024.
26. Gupta N, Goyal M, Wu CH, Wu GY. The Molecular and Structural Basis of HBV-resistance of Nucleos(t)ide Analogs. *Journal of Clinical and Translational Hepatology*. 2014; 2: 202-11.
27. Kementerian Kesehatan RI. Pusat Data dan Informasi. Jakarta Selatan: Kementerian Kesehatan RI; 2014.
28. Badan Penelitian dan Pengembangan Kesehatan Kementrian Kesehatan RI. Riset Kesehatan Dasar 2013. Jakarta: Kementerian Kesehatan RI; 2013.
29. Kim DH, Kang HS, Kim K-H. Roles of hepatocyte nuclear factors in Hepatitis B virus infection. *World J Gastroenterol*. 2016; 22: 7017.
30. AMN Healthcare Education. Hepatitis B: Pathophysiology, Protection, and Patient. 2013.

31. Tu T, Urban S. Virus entry and its inhibition to prevent and treat Hepatitis B and Hepatitis D virus infections. *Curr Opin Virol.* 2018; 30: 68–79.
32. Soemoharjo S, Gunawan S. Hepatitis B kronik dalam: *Buku Ajar Ilmu Penyakit Dalam*. Edisi 6. Jakarta: Interna Publishing. 2014: 1963-71.
33. Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic Hepatitis B Virus Infection. *Lancet.* 2018; 392: 2313–24.
34. Kumar AA, Busca. Innate immune responses in Hepatitis B virus (HBV) infection. *Virology Journ.* 2014; 11:22.
35. European Association for the Study of the Liver. EASL. EASL 2017 Clinical Practice Guidelines on the management of Hepatitis B virus infection. *J Hepatol.* 2017;67: 370 – 98.
36. Nguyen MH, Wong G, Gane E, Kao J, Dusheiko G. Hepatitis B Virus: Advances in Preventivon, Diagnosis, and Therapy. *Clinical Microbiology Reviews.* 2020; 33(2): 1-38
37. Heller T, Phiri V, Kumwenda T, Mzumara W, Vinikoor MJ, Rambiki E, et al. 2024. Point of care ultrasound to inform antiviral treatment initiation in chronic hepatitis B virus infection in low resource settings-the PUSH protocol. *The Ultrasound Journal.* 2024; 16(18): 1-10.
38. Zacher BJ, Moriconi F, Bowden S, Hammond R, Louisirirochanakul, Phisalprapa P, *et al.* Multicenter evaluation of the elecsys Hepatitis B surface antigen quantitative assay. *Clinical and Vaccine Immunology.* 2011;18(11):1943-50.
39. Primadharsini PP, Wibawa ID. Correlation between Quantitative HBsAg and HBV-DNA in Chronic Hepatitis B Infection. *The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy.* 2013.14(1):9-12.
40. Oeda S, Tanaka K, Oshima A, Matsumoto Y, Sueoka E, Takahashi H. Diagnostic Accuracy of Fibroscan and Factors Affecting Measurements. *Diagnostics.* 2020; 10 (940):1-11.

41. Sarin SK, Kumar M, Lau GK, Abbass Z, Chan HL, Chen CJ, et al. Asian-Pacific Clinical Practice Guidelines on the management of Hepatitis B: a 2015 Update. *Hepatology Int.* 2016; 10:1-98.
42. Lesmana CR, Gani RA, Hasan I, Samadibrata M, Sulaiman AS, Pakasi LS, et al. Significant hepatic histopathology in chronic Hepatitis B patients with serum ALT less than twice ULN and high HBV-DNA levels in Indonesia. *J Dig Dis.* 2011; 476-80.
43. Terrault Norah A, Lok Anna S.F, J Brian. McMahon, Chang Kyong-Mi, P Jessica. Hwang, Jonas Maureen M, et al. Update on prevention, diagnosis and treatment of chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. *Hepatology Int.* 2018;67(4):1560-99.
44. Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic Hepatitis B. *World J Hepatol.* 2017; 9(5): 227-41.
45. World Health Organization. WHO global health sector strategy on viral Hepatitis. Geneva: World Health Organization; 2016
46. Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. *Experimental Biology and Medicine.* 2020. Jan;245(2):96-108.
47. Xu R, Zhang Z, Wang FS. Liver fibrosis: mechanisms of immune-mediated liver injury. *Cellular & Molecular Immunology.* 2011: 1-6
48. Kang J, Lee M. Noninvasive Diagnostic and Prognostic Assessment Tools for Liver Fibrosis and Cirrhosis in Patients with Chronic Liver Disease. *2017;2:35-75.*
49. Pellicoro A, Ramachandra P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. *Nature Reviews Immunology.* 2014;14(3), 181–94.

50. Illoeje UH, Yang HI, Su J, Jen CL, Yu SL, Chen CJ. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/ Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating Hepatitis B viral load *Gastroenterology*. 2016;130(3):678-86.
51. Chen CJ, Yang HI, Su J, Jen CL, Yu SL, Lu SN, *et al*. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum Hepatitis B virus DNA level. *JAMA*. 2016;295(1):65-73.
52. Lin DY, Sheen IS, Chiu CT, Lin SM, Kuo YC, Liaw YF. Ultrasonographic changes of early liver cirrhosis in chronic Hepatitis B: A longitudinal study. *Journal of clinical ultrasound*. 2015; 21: 303-08.
53. Chen YP, Dai L, Wang JL, Zhu YF, Feng XR, Hou JL. Model consisting of ultrasonographic and simple blood indexes accurately identify compensated Hepatitis B cirrhosis. *Gastroenterol Hepatol*. 2018; 23: 1228-34.
54. Wong G, Wong F, Choi P, Chan H, Chan A. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic Hepatitis B. *Aliment Pharmacol Ther*. 2010: 1095-1103.
55. Uzlova N, Stridova KM, Merta D, Rychlik I, Frankova S. Transient Elastography as the First Line Assessment of Liver Fibrosis and Its Correlation with Serum Markers. *Medicina*. 2023; 59 (752): 1-12.
56. Gupta E, Khodare A, Rani N, Singh G, Aggarwal K, Sharma M. Performance evaluation of Xpert HBV viral Load (VL) assay: Point of care molecular test to strengthen and decentralize management of chronic hepatitis B (CHB) infection. *Journal of Virological Methods* 290. 2021; 114063: 1-6.
57. Andriani Y, Sari CP, Setyaningrum N. Evaluasi pengobatan pada pasien Hepatitis B rawat jalan di Rumah Sakit Yogyakarta. 2020;(Nov):65-75.
58. Luo H, Peng S, Ouyang W, Tan Y, Jiang T, Tang L, *et al*. Assessment of liver fibrosis by transient elastography and multi-parameters model in young

- children with chronic hepatitis B virus infection. *BMC Infectious Diseases*, 2022. 22(1).
59. Loustaud-Ratti V, Jacques J, Debette-Gratien M, Carrier P. Hepatitis B and elders: An underestimated issue. In *Hepatology Research*. Blackwell Publishing Ltd. 2016: 46 (1), pp. 22–28.
60. CDC. Number and rate of newly reported cases† of chronic Hepatitis B virus infection, by demographic characteristics — United States, 2021. Centers for Disease Control and Prevention.
61. Wang SH, Chen PJ, Yeh SH. Gender disparity in chronic hepatitis B: Mechanisms of sex hormones. *JGH Journal of Gastroenterology and Hepatology*, 2015; 30, 1237–45.
62. Ruggieri A, Gagliardi MC, Anticoli S. Sex-dependent outcome of Hepatitis B and C viruses infections: Synergy of sex hormones and immune responses? *Front Immunol*. 2018;9:1-7.
63. Yu D, Heathcote J. Tenofovir in the treatment of chronic hepatitis B. *Therapy in Practice*. 2011; 8(5): 527-44.
64. Buti M, Roade L, Riveiro-Barciela M, Esteban R. Optimal management of chronic Hepatitis B patients receiving nucleos(t)ide analogues. *Liver Int*. 2020;40(1):15-21.
65. Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, *et al*. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic Hepatitis B virus infection. *Liver Int*. 2019;39(10):1868-75.
66. Agarwal K, Fung S, Seto WK, Lim YS, Gane E, Janssen HL, *et al*. A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic Hepatitis B (CHB): efficacy and safety results at week 96. *J Hepatol*. 2017;66(1):478.
67. Kitrinou KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, *et al*. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. *Hepatology*. 2014;59(2):434-42.

68. Idilman R. The summarized of EASL 2017 Clinical practice guidelines on the management of Hepatitis B virus infection. *Turkish J Gastroenterol.* 2017; 28(5): 412-16.
69. Papatheodoridis GV, Chan HLY, Hansen BE, Janssen HLA, Lampertico P. Risk of hepatocellular carcinoma in chronic Hepatitis B: Assessment and modification with current antiviral therapy. *J Hepatol.* 2015;62(4):956-67.
70. Mauss S, Berg T, Rockstroh J, Sarrazin C WH. *Hepatology*, Tenth Edition. 2020:1-61.
71. Cho H, Lee YB, Ha Y, Chon YE, Kim MN, Lee JH, *et al.* Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with Tenofovir disoproxil fumarate: a prospective observational study. *BMC Gastroenterology.* 2023; 210 (23) :1-8.
72. Linh HP, Hien LTH, Tiep HV, Dang DC, Manh NKH. Study on Fibrosis change with transient elastography in chronic hepatitis b virus treatment with tenofovir. *Gut.* 2020; 69 (2):A88-A89.
73. Nag A, Ghosh S, Sarkar S, Mondal SS, Hossain E, Mandal SK. A study on outcome of hepatic fibrosis in chronic hepatitis B patients on antiviral therapy. *Asian Journal of Medical Science.* 2024; 15(2): 98-102.
73. Shipley LC, Axley PD, Singal AK. Liver Fibrosis: A Clinical Update. *EMJ Hepatol.* 2019; 7: 105-17.



